CLINICALREVIEW
Trial timeline revised
Compare the current record with its prior registry version.
ClinicalTrials.govMonitoring, configured for your team
Keep watch on the assets that matter.
Tell us which drugs and companies you follow. We set up the coverage, configure your watch, and give your team a source-linked read on what changed and what deserves attention.
Source-linked updates
Daily or weekly reads
Priority-gated alerts
ASSET WATCH
ILLUSTRATIVE VIEW
YOUR WATCHLIST
Changes to review
REGULATORYREVIEW
Product label updated
Inspect the section change before updating the team brief.
DailyMed SPLEVIDENCEDIGEST
New publication linked
Check its relevance to the watched asset and indication.
Publication recordIllustrative signal types. Actual updates depend on source coverage and refresh cadence.
One place to see the change, inspect the source, and decide what happens next.
How it works
From your watchlist to a working monitor.
Watchtower is set up around the assets and decisions your team actually owns.
Choose what to follow
Share the products, competitors, and companies that matter, plus the questions your team needs answered.
We prepare the coverage
We match the right asset identities, load available source data, check readiness, and configure the watch from your perspective.
Get a decision read
Receive a daily or weekly digest. Optional event alerts flag qualifying changes between regular reads.
Each watch has a review cadence and priority threshold. Event alerts follow those settings and the publication cadence of each source.
What comes into view
Changes across the asset lifecycle.
Watchtower connects the records behind your watch, so a new signal comes with the context needed to review it.
Talk through your coverageTrials and milestones
Status, enrollment, dates, results, and registry changes.
FDA and label updates
Approvals, safety and label changes, exclusivity, and other regulatory events.
New evidence
Publications, grants, and related scientific activity.
Market context
Public pricing, utilization, company filings, and competitive signals.
Source availability varies by asset and usage rights. Watchtower shows coverage and freshness instead of treating missing data as zero.
Built for review
A signal is the start of the conversation.
Each read helps your team answer three practical questions:
- What changed? A concise summary of the source update.
- Why does it matter? Context for the watched asset and your perspective.
- What next? A reviewable action, with a path back to the evidence.
Brand-level and molecule-level evidence stay distinct, so shared science is not presented as exclusive to one brand.
Get started
Tell us what to watch.
Share the assets and changes your team cares about. We’ll review your request and follow up to scope a monitoring setup.
01 / YOUR ASSETS
02 / YOUR PRIORITIES
03 / YOUR CADENCE